| Literature DB >> 24589717 |
Juan Carlos Almagro1, Gary L Gilliland2, Felix Breden3, Jamie K Scott3, Devin Sok4, Matthias Pauthner4, Janice M Reichert5, Gustavo Helguera6, Raiees Andrabi4, Robert Mabry7, Mathieu Bléry8, James E Voss4, Juha Laurén9, Lubna Abuqayyas10, Stefan Barghorn11, Eshel Ben-Jacob12, James E Crowe13, James S Huston14, Stephen Albert Johnston15, Eric Krauland7, Fridtjof Lund-Johansen16, Wayne A Marasco17, Paul W H I Parren18, Kai Y Xu19.
Abstract
The 24th Antibody Engineering & Therapeutics meeting brought together a broad range of participants who were updated on the latest advances in antibody research and development. Organized by IBC Life Sciences, the gathering is the annual meeting of The Antibody Society, which serves as the scientific sponsor. Preconference workshops on 3D modeling and delineation of clonal lineages were featured, and the conference included sessions on a wide variety of topics relevant to researchers, including systems biology; antibody deep sequencing and repertoires; the effects of antibody gene variation and usage on antibody response; directed evolution; knowledge-based design; antibodies in a complex environment; polyreactive antibodies and polyspecificity; the interface between antibody therapy and cellular immunity in cancer; antibodies in cardiometabolic medicine; antibody pharmacokinetics, distribution and off-target toxicity; optimizing antibody formats for immunotherapy; polyclonals, oligoclonals and bispecifics; antibody discovery platforms; and antibody-drug conjugates.Entities:
Keywords: antibody therapeutics,; antibody-drug conjugate; bispecific antibodies; protein scaffolds
Mesh:
Substances:
Year: 2014 PMID: 24589717 PMCID: PMC4011904 DOI: 10.4161/mabs.28421
Source DB: PubMed Journal: MAbs ISSN: 1942-0862 Impact factor: 5.857